Alternative psychotherapy approaches for social anxiety disorder

Hypnotherapy modulating early and late event-related potentials components of face processing in social anxiety

Background

Hypnotherapy has a potential role in modulating attention bias to treat social anxiety disorder (SAD). This study aimed to verify whether hypnotherapy can reduce social anxiety by changing attentional bias. The primary objective of our study is to explore the influence of hypnosis on various aspects of attention processes, specifically focusing on how it affects attention bias and social anxiety.

Methods

This study included 69 participants with SAD who were assigned to three groups based on their scores on the Liebowitz Social Anxiety Scale (LSAS). The experimental group (n = 23) received a hypnosis treatment once a week, for a total of six sessions, while the control group (n = 23) and the baseline group (n = 23) did not receive any treatment. To evaluate whether hypnosis could alleviate SAD and attention bias towards threatening stimuli, we employed questionnaires and an odd-one-out task accompanied by electroencephalography (EEG) recordings.

Results

Under the attention sensitivity conditions, the experimental group exhibited a reduced N170 and LPP at the posttest stage, and a similar N170 and LPP reduction under the attention disengagement conditions. Notably, the symptom improvements were positively correlated with the reduction in N170 and LPP amplitude across conditions.

Conclusion

Hypnosis treatment modulates the early face processing and late emotional evaluation of threat-related stimuli in SAD patients. These findings suggest that N170 and LPP are important biomarkers for the treatment of SAD.

Social anxiety disorder: radio electric asymmetric conveyor brain stimulation versus sertraline

PURPOSE

Social anxiety disorder (SAD) is a disabling condition that affects almost 5% of the general population. Many types of drugs have shown their efficacy in the treatment of SAD. There are also some data regarding psychotherapies, but no data are available today about the efficacy of brain stimulation techniques. The aim of the study is to compare the efficacy of noninvasive brain stimulation neuro psycho physical optimization (NPPO) protocol performed by radio electric asymmetric conveyor (REAC) with that of sertraline in adults with SAD.

PATIENTS AND METHODS

Twenty SAD patients on sertraline were compared with 23 SAD patients who refused any drug treatment and who chose to be treated with NPPO-REAC brain stimulation. This was a 6-month, open-label, naturalistic study. Patients on sertraline received flexible doses, whereas NPPO-REAC patients received two 18-session cycles of treatment. Clinical Global Improvement scale items "much improved" or "very much improved" and Liebowitz Social Anxiety Scale total score variation on fear and avoidance components were used to detect the results. The statistical analysis was performed with t-test. All measures <0.05 have been considered statistically significant.

RESULTS

Ten of 23 subjects on NPPO-REAC and six of the 20 taking sertraline were much improved or very much improved 1 month after the first NPPO-REAC cycle (t1). Sixteen of the subjects on NPPO-REAC and ten of the subjects taking sertraline were much improved or very much improved 1 month after the second NPPO-REAC cycle (t2). In respect of the Liebowitz Social Anxiety Scale, at t1 NPPO-REAC resulted in statistically more efficacy for sertraline on both fear and avoidance total scores. At t2, NPPO-REAC resulted in statistically more efficacy for sertraline on fear but not on avoidance.

CONCLUSION

NPPO-REAC is an effective treatment for SAD, allowing substantial and clinically meaningful reductions in symptoms and disability in comparison with sertraline.

A pilot study of clonazepam versus psychodynamic group therapy plus clonazepam in the treatment of generalized social anxiety disorder

BACKGROUND

Both psychodynamic group therapy (PGT) and clonazepam are used as treatment strategies in reducing symptoms of generalized social anxiety disorder (GSAD). However, many individuals remain symptomatic after treatment with PGT or clonazepam.

METHOD

Fifty-eight adult outpatients with a diagnosis of GSAD according to DSM-IV were randomized to 12 weeks PGT plus clonazepam or clonazepam. The Clinical Global Impression-Improvement (CGI-I) Scale was the primary efficacy measure. Secondary efficacy measures included the Liebowitz Social Anxiety Scale (LSAS) total score, the World Health Organization Instrument to Assess Quality of Life-Brief (WHOQOL-Bref) Scale and the Beck Depression Inventory (BDI).

RESULTS

CGI-I data from 57 patients (intent-to-treat population) showed that patients who received PGT plus clonazepam presented significantly greater improvement than those who received clonazepam (P=0.033). There were no significant differences between the two groups in the secondary efficacy measures.

CONCLUSIONS

Our study suggests that the combination of PGT with clonazepam may be a promising strategy for the treatment of GSAD, regarding gains in the global functioning. However the present study failed to detect more specific changes in social anxiety symptomatology between the two groups.

Psicoterapia psicodinâmica em grupo para fobia social generalizada

OBJETIVOS: O objetivo deste estudo é verificar a efetividade do tratamento psicodinâmico em grupo de pacientes com fobia social generalizada. MÉTODOS: 30 pacientes foram incluídos em um estudo randomizado, simples-cego, comparando Terapia Psicodinâmica de Grupo (TPG) com um Grupo de Controle Placebo com Credibilidade (CPC). A TPG foi conduzida em 12 sessões de terapia de orientação psicodinâmica em grupo. Os pacientes do grupo controle receberam um pacote de aulas-discussões e tratamento de apoio por 12 semanas, que foi comparado à TPG. Todos os participantes preencheram a Escala de Liebowitz para Ansiedade Social (LSAS), a Escala Hamilton de Ansiedade (HAM-A) e a Escala de Impressão Clínica Global (CGI), na entrevista inicial e na 12ª semana de tratamento. Os dados foram analisados com uma ANOVA de medidas repetidas. Pacientes em vigência de tratamento farmacológico ou psicoterápico foram excluídos. RESULTADOS: Ambos os grupos apresentaram melhora na maioria das medidas. Na LSAS, os pacientes da TPG obtiveram melhora superior aos do grupo controle, ao cabo de 12 semanas (F1,28=4.84, p=0.036). Nas medidas basais dos sujeitos que completaram o estudo, não houve diferença entre os grupos em variáveis demográficas e de desfecho. CONCLUSÃO: Neste estudo, a TPG foi superior ao tratamento placebo com credibilidade no tratamento da fobia social generalizada, em um ensaio clínico randomizado, simples-cego, de 12 semanas.